Head & neck cancer
1 trial- 2019KEYNOTE-048R/M HNSCCIn 882 patients with untreated recurrent or metastatic squamous-cell head and neck cancer, pembrolizumab or pembrolizumab + platinum + 5-FU improved overall survival compared with cetuximab + platinum + 5-FU (EXTREME).